A Phase 2 interventional study of Dalpiciclib and Pyrotinib in Breast Neoplasm, Breast Cancer and Breast Tumors, sponsored by Fudan University. Recruiting at 1 site in China. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-05-28.
Sponsored by Fudan University · Phase 2, Interventional, and Treatment
How we know · 64 judgments
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 65 studies in Triple Negative Breast Neoplasms by Fudan University — 35 open to participants now, 39 under way, 12 of them phase 3. Triple Negative Breast Neoplasms · Fudan University.
Among the 65 studies in Triple Negative Breast Neoplasms by Fudan University, this one is the 6th largest by planned enrollment of the 62 interventional ones that give a count, is one of 5 that started in 2022, is one of 41 in phase 2, reaches primary completion later than 22 of the 38 other live ones, and was the 31st registered.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
Browse Triple Negative Breast Neoplasms studies →35 of the 65 studies in Triple Negative Breast Neoplasms by Fudan University are open now, in 1 country. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–75 · Women only
Fudan University · Sites in China
Ages 18–80
Fudan University · Sites in China
Ages 18–70
Fudan University · Sites in China
Ages 18+ · Women only
Fudan University · Sites in China
Ages 18–70
By country, each count listing its studies:
Of the 329 Triple Negative Breast Neoplasms studies recruiting now, 229 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 18 Years to 70 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
65 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 44 · Phase 3 16 · Phase 4 2
First in 2007; this study’s year is marked. 5 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 716 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Median enrollment 110 across the 62 interventional studies, 300 across the 3 observational. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.
6 of the studies in Triple Negative Breast Neoplasms by Fudan University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06793332Fudan UniversityBrAin Metastasis in tripLe Negateive Breast Cancer: IvoneScimab and Trop2 ADC | 2026-12-31 |
| NCT05076682Fudan UniversityReverse Triple Negative Immune Resistant Breast Cancer | 2026-12-31 |
| NCT06798506Fudan UniversityReal-world Patient-reported Outcome of Sacituzumab Govitecan in Chinese Metastatic Triple-negative Breast Cancer | 2027-01-15 |
| NCT07705438Fudan UniversityGranzyme B-PET: Predicting Immunotherapy Efficacy in TNBC | 2027-05-28 |
| NCT06731153Fudan UniversityJAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC | 2027-06 |
Add all 6 to your calendar (.ics) → With an account.
Among the 65 studies in Triple Negative Breast Neoplasms by Fudan University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to establish a prospective, single-center platform research based on clinical subtypes to explore precision neoadjuvant therapy in patients with operable breast cancer who met the indications for neoadjuvant chemotherapy and by the update of basic translational research in the center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs, verified the effectiveness of new targeted drugs in neoadjuvant therapy.
FASCINATE-N is a platform that will compare the efficacy of novel drugs alone or in combination with standard chemotherapy with the efficacy of standard therapy alone. The goal is to identify improved treatment regimens for subsets on the basis of clinical subtyping. In this trial, breast cancer patients eligible for inclusion can be randomly divided into the precision treatment group and conventional neoadjuvant chemotherapy group according to molecular typing and subtyping. The research therapy arm can be updated with the update of basic translational research in our center, especially the refinement of typing, the discovery of new targets and the development of novel targeted drugs. As described for previous adaptive trials, regimens that show to be more effective than standard therapy will graduate from the trial with their corresponding biomarker signature(s). Regimens will be dropped if they show a low probability of improved efficacy with any biomarker signature. New drugs will enter as those that have undergone testing complete their evaluation.
1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 441 are open to participants now.
This study's planned enrollment of 716 is above the median of 60 across 1,053 interventional studies indexed under Triple Negative Breast Neoplasms.
Browse Triple Negative Breast Neoplasms studies →Fudan University is the lead sponsor of 1,319 studies on the registry; 647 are open to participants now.
Compared within Triple Negative Breast Neoplasms, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Breast Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
If patients were hormone receptor-positive (HR+) and HER2-negative (HER2-) defined as similarity network fusion 1(SNF1) subtype
Drug: Dalpiciclib · Drug: Goserelin · Drug: Letrozole
If patients were HR+HER2- with SNF1 subtype
Drug: Nab paclitaxel · Drug: Carboplatin
If patients were HR+HER2- with SNF2 subtype
Drug: Nab paclitaxel · Drug: Carboplatin
If patients were HR+HER2- with SNF3 subtype
Drug: Nab paclitaxel · Drug: Carboplatin
If patients were HR+HER2- with SNF4 subtype
Drug: Nab paclitaxel · Drug: Carboplatin
If patients were HR+HER2-low with SNF4 subtype
Drug: SHR-A1811
If patients were HR+HER2-low with SNF4 subtype
Drug: Nab paclitaxel · Drug: Carboplatin
If patients were triple-negative breast cancer with immunomodulatory (IM) subtype
Drug: Camrelizumab · Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide
If patients were triple-negative breast cancer with IM subtype
Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide
If patients were triple-negative breast cancer with basal-like immune suppressed (BLIS) subtype
Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Fluzoparib
If patients were triple-negative breast cancer with BLIS subtype
Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide
If patients were triple-negative breast cancer with androgen receptor positive HER2 activated (AR HER2) subtype
Drug: Pyrotinib · Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide
If patients were triple-negative breast cancer with AR HER2 subtype
Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide
If patients were HR-HER2-low
Drug: SHR-A1811
If patients were HR-HER2-low
Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide
If patients were triple-negative breast cancer with other subtypes
Drug: SHR-A1921
If patients were triple-negative breast cancer with other subtypes
Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide
If patients were HR+HER2+
Drug: Pyrotinib · Drug: SHR-A1811
If patients were HR+HER2+
Drug: Pertuzumab · Drug: Trastuzumab · Drug: Nab paclitaxel · Drug: Carboplatin
If patients were HR-HER2+
Drug: Pyrotinib
If patients were HR-HER2+
Drug: Pertuzumab · Drug: Trastuzumab · Drug: Nab paclitaxel · Drug: Carboplatin
If patients were HR+HER2- with similarity network fusion 2 (SNF2) subtype
Drug: SHR-1316 · Drug: Nab paclitaxel · Drug: Carboplatin
If patients were HR+HER2- with similarity network fusion 3 (SNF3) subtype
Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Fluzoparib
If patients were HR+HER2- with similarity network fusion 4 (SNF4) subtype
Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Apatinib
If patients were triple-negative breast cancer with other subtypes
Drug: SHR-1316 · Drug: SHR-A1921
If patients were HR+HER2+
Drug: SHR-A1811
If patients were HR-HER2+
Drug: Pyrotinib · Drug: SHR-A1811
If patients were HR-HER2-low
Drug: SHR-A1811 · Drug: Camrelizumab · Drug: Famitinib
If patients were HR+HER2- with similarity network fusion 2 (SNF2) subtype
Drug: Dalpiciclib · Drug: Goserelin · Drug: Letrozole
If patients were HR+HER2- with similarity network fusion 2 (SNF2) subtype
Drug: SHR-1316 · Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Famitinib
If patients were HR+HER2- with similarity network fusion 3 (SNF3) subtype
Drug: Dalpiciclib · Drug: Goserelin · Drug: Letrozole
If patients were HR+HER2- with similarity network fusion 4 (SNF4) subtype
Drug: SHR-A1921
If patients were HR+HER2-
Drug: Cyclophosphamide · Drug: HB1801 · Drug: LEM
If patients were HR+HER2-
Drug: Cyclophosphamide · Drug: HB1801 · Drug: LEM
If patients were HR+HER2-low
Drug: SHR-A1811 · Drug: SHR-1316 · Drug: Famitinib
If patients were HR+HER2-low
Drug: Famitinib · Drug: TQB2102 · Drug: Benmelstobart
If patients were HR+HER2-
Drug: TQB2102 · Drug: Anlotinib · Drug: TQB2868
If patients were HR+HER2-low
Drug: Nab paclitaxel · Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Ivonescimab
TNBC
Drug: SHR-A1811 · Drug: SHR-1316 · Drug: Famitinib
TNBC
Drug: SHR-A1811 · Drug: SHR-1316
If patients were HR-HER2-low
Drug: TQB2102 · Drug: Benmelstobart
If patients were HR-HER2-low
Drug: TQB2102 · Drug: Benmelstobart · Drug: Anlotinib
TNBC
Drug: TQB2102 · Drug: TQB2868
TNBC
Drug: Carboplatin · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: paclitaxel
If patients were HER2+
Drug: JSKN003
If patients were HER2+
Drug: SHR-A1811 · Drug: Pertuzumab · Drug: Trastuzumab · Drug: Nab paclitaxel · Drug: Carboplatin
If patients were HER2+
Drug: SHR-A1811
If patients were HER2+
Drug: Pertuzumab · Drug: Trastuzumab · Drug: Nab paclitaxel · Drug: Carboplatin
If patients were HER2+
Drug: Pyrotinib · Drug: SHR-A1811
If patients were HER2+
Drug: SHR-A1811 · Drug: SHR-4602
If patients were HER2+
Drug: SHR-A1811 · Drug: HRS-4508
If patients were HER2+
Drug: SHR-A1811 · Drug: Pertuzumab · Drug: HRS-4508
If patients were HR+HER2-
Drug: Nab paclitaxel · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: JS207
If patients were HR+HER2+
Drug: SHR-A1811 · Drug: Goserelin · Drug: Letrozole · Drug: HRS-6209
If patients were HR+HER2+
Drug: SHR-A1811 · Drug: Goserelin · Drug: Letrozole
If patients were TNBC
Drug: JS207 · Drug: 9MW2821
If patients were HR+HER2-
Drug: JS207 · Drug: 9MW2821
If patients were HER2+
Drug: SHR-A1811 · Drug: Pertuzumab · Drug: Trastuzumab · Drug: paclitaxel
If patients were HER2+
Drug: Pertuzumab · Drug: IBI354
TNBC
Drug: SHR-A1811 · Drug: SHR-1316 · Drug: Nab paclitaxel · Drug: Carboplatin
The TN11 arm explores AI-guided multidisciplinary precision therapy in TNBC. Patients are stratified using an established digital pathology-based AI model that predicts sensitivity to the combination therapy of Paclitaxel, Carboplatin, Camrelizumab and Famitinib. Patients predicted to be sensitive (TN11-1) receive this combination therapy directly.
Drug: Camrelizumab · Drug: Carboplatin · Drug: Famitinib · Drug: paclitaxel
TNBC patients predicted to be non-sensitive (TN11-2) to the combination therapy of Paclitaxel, Carboplatin, Camrelizumab and Famitinib first undergo stereotactic body radiation therapy (SBRT). SBRT is delivered to the primary tumor in 3 fractions of 8 Gy (total 24 Gy) over 3-5 days. Following SBRT, patients receive the combination therapy of Paclitaxel, Carboplatin, Camrelizumab and Famitinib.
Drug: Camrelizumab · Drug: Carboplatin · Drug: Famitinib · Drug: paclitaxel · Radiation: Stereotactic Body Radiation Therapy (SBRT)
Patients with HR+HER2- breast cancer, clinical stage cT1c-4, cN0-3, M0, with either tumor grade ≥2 or Ki-67 ≥20%. Patients first undergo stereotactic body radiotherapy (SBRT) to the primary tumor, followed by combination therapy of Paclitaxel + Epirubicin + Cyclophosphamide + Camrelizumab + Famitinib.
Drug: Camrelizumab · Drug: Epirubicin · Drug: Cyclophosphamide · Drug: Famitinib · Drug: paclitaxel · Radiation: Stereotactic Body Radiation Therapy (SBRT)
an oral cyclin-dependent kinases (CDK) 4/6 inhibitor
Also known as: SHR-6390
an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor
an anti-HER2 antibody-drug conjugate (ADC)
an anti-programmed death ligand 1 (PD-L1) antibody
an anti-programmed death-1 (PD1) antibody
Also known as: SHR-1210
Trophoblast cell-surface antigen 2 (TROP2) ADC
Pertuzumab
Trastuzumab
goserelin
letrozole
Albumin paclitaxel
Carboplatin
Epirubicin
Cyclophosphamide
an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor
Also known as: SHR-3162
tyrosine kinase inhibitors
tyrosine kinase inhibitors
Albumin docetaxel
liposome-entrapped mitoxantrone
an anti-HER2 ADC
an anti-PDL1 antibody
an tyrosine kinase inhibitor
anti-PD-1/TGF-βRII
an anti-PD-1/VEGF bispecific antibody
an anti-PD-1/VEGF bispecific antibody
an anti-HER2 ADC
an HER2 inhibitor
an anti-HER2 ADC
paclitaxel
an oral cyclin-dependent kinases 4 (CDK4) inhibitor
a Nectin-4 antibody-drug conjugate (ADC)
an anti-HER2 ADC
Stereotactic Body Radiation Therapy (SBRT) is performed within 5 calendar days prior to the initiation of drug therapy. SBRT is delivered to the primary tumor in 3 fractions of 8 Gy each (total 24 Gy) over 3-5 days.
Pathological complete response rate (pCR)
Pathological complete response rate
Time frame: through study completion, up to 24 weeks
invasive disease-free survival (iDFS)
To determine three-year invasive disease-free survival (iDFS) among the treatment arms
Time frame: Three-year Post-surgery Follow-up
Overall response rate (ORR)
Complete response (CR) + partial response (PR)
Time frame: up to 24 weeks
CTCAE scale (V4.0)
4\) To evaluate the rate of adverse effects of patient by the standard CTCAE scale (V4.0)
Time frame: through study completion, an average of 1 year
Evaluate gene expression profile during treatment
To measure gene expression profile of baseline and sequential tumor samples during treatment, through RNA-seq platform
Time frame: through study completion, up to 24 weeks
Number of peripheral blood mononuclear cells (PBMC) count during treatment
To measure number of peripheral blood mononuclear cells (PBMC) count from baseline and sequential blood samples during treatment, through Flow CytoMetry platform
Time frame: through study completion, up to 24 weeks
Biomarker analysis
Tumor tissues, paracancerous tissues, ctDNA, blood, fecal samples, tumor pathological whole slide images and MRI images collected from study participants will be used for discovering exploratory biomarkers. The associations between these biomarkers and treatment responses disease status will be investigated.
Time frame: through study completion, up to 24 weeks
Plan to share: No
Started Nov 2022 (actual). Primary completion is estimated for Dec 2027, 61 months after the start.
Of 220 non-industry phase 2 interventional studies under Triple Negative Breast Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 38 and three quarters within 99. This study's planned 61 months is close to that.
Counting every sponsor, half of 255 studies reached it within 59 months; a quarter within 37 and three quarters within 94.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Dalpiciclib · Pyrotinib · Trastuzumab rezetecan · Adebrelimab · Camrelizumab · Tizetatug rezetecan · Pertuzumab · Trastuzumab · Goserelin · Letrozole · Albumin-Bound Paclitaxel · Carboplatin · Epirubicin · Cyclophosphamide · Fluzoparib · Apatinib · Famitinib · Docetaxel · Anti-HER2/Topoisomerase I Inhibitor ADC TQB2102 · Anti-PD-1/Anti-TGF-beta Bifunctional Fusion Protein TQB2868 · Ivonescimab · Anti-PD-1/Anti-VEGF Bispecific Antibody JS207 · Anbenitamab repodatecan · HRS-4508 · SHR-4602 · Paclitaxel · HRS-6209 · Anti-HER2 Antibody-drug Conjugate IBI354
Triple Negative Breast Neoplasms →